Back to Archived News
HemoShear Announces Issuance of New U.S. Patent For its Human Cell-Based Surrogate Systems
Tuesday, October 12, 2010
Technology Replicates Biology of Healthy and Diseased Organ Systems
Charlottesville, VA -- HemoShear LLC, a biotechnology research company and leading developer of human cell-based surrogate systems for discovery and assessment of new drug compounds, today announced that the U.S. Patent and Trademark Office (USPTO) has granted it patent no. 7,811,782 entitled “Use of An In VitroHemodynamic Endothelial/Smooth Muscle Cell Co-Culture Model to Identify New Therapeutic Targets for Vascular Disease.” This patent covers HemoShear’s core technology which replicates the biology of healthy and diseased human organ systems by applying physiologically-relevant hemodynamic (blood flow) forces and other conditions to organ-specific primary cells.
“We are very proud of this important milestone in building HemoShear. The issuance of HemoShear’s first patent validates the innovation behind our core technology and the strong scientific expertise of our founders, Drs. Brett Blackman and Brian Wamhoff. Physiologically-relevant hemodynamic forces are critical for vascular cell survival and to accurately recreate human biology in the laboratory,” said Jim Powers, HemoShear’s CEO. “Our technology, in combination with the expertise of our scientists, is the basis for HemoShear’s partnerships with pharmaceutical customers aimed at accelerating new drug discovery and reducing risk of failures in their drug research and development efforts.”
In addition to the above newly issued patent, the Company has patent applications pending in all major international markets and plans future patent applications for enhancements of the core technology.
About HemoShear, LLC
HemoShear LLC is a biotechnology research company that combines its scientific expertise with its unique technology in partnership with pharmaceutical companies to accelerate drug discovery and development. HemoShear has scientific expertise in the areas of human and animal biology, bioinformatics and molecular profiling for target identification and validation, cell-signaling pathway analysis, sophisticated methods to quantify target genes and proteins, assessment of molecular pharmacology, and methods to determine mechanisms of action for drug efficacy and safety. HemoShear’s systems can replicate the biology of human organs in both healthy and disease states by applying physiologically accurate blood flow forces to primary cell cultures. HemoShear is currently working with several large pharmaceutical companies on projects that span the drug discovery and development spectrum. HemoShear is a privately held company located in Charlottesville, Virginia. To learn more about HemoShear, visit www.hemoshear.com.
Back to Archived News